Embecta Corp

Embecta Corp. engages in manufacturing and distributing medical devices used in the treatment of diabetes. It delivers insulin for diabetic patients to improve their lives. The company is headquartered in Parsippany, NJ.

Earnings data Q1 2023

Earnings data Q2 2023

Innovage Holding Corp

OncoCyte

The Zacks Medical - Services industry is growing on digital healthcare adoption. EMBC, INNV and OCX are set to gain the most.

3 Medical Services Stocks to Buy Amid Industry Challenges

Piedmont Lithium

Textron

PLL, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 24, 2023.

Best Momentum Stocks to Buy for February 24th

Deere & Company

LCNB

PLL, TXT, EMBC, DE and LCNB have been added to the Zacks Rank #1 (Strong Buy) List on February 24, 2023.

New Strong Buy Stocks for February 24th

Deutsche Telekom AG

DTEGY, TXT and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 24, 2023.

Best Value Stocks to Buy for February 24th

Highlights the critical role people with diabetes play in their own care and treatment Highlights the critical role people with diabetes play in their own care and treatment

embecta sponsors educational symposium at ATTD 2023

CVR Energy

Inspire Medical Systems Inc

EMBC, INSP, REPYY, BZLFY and CVI have been added to the Zacks Rank #1 (Strong Buy) List on February 21, 2023.

New Strong Buy Stocks for February 21st

Twin beats and raised guidance make for a good day on the market for the diabetes care specialist.

Why Embecta Stock Popped by Nearly 13% Today

Embecta Corp. (NASDAQ:EMBC ) Q1 2023 Earnings Conference Call February 14, 2023 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President, Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Marie Thibault - BTIG Travis Steed - Bank of America Operator Welcome, ladies and gentlemen to the Fiscal First Quarter 2023 Embecta Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available in the company's website for replay following the completion of this call.

Embecta Corp. (EMBC) Q1 2023 Earnings Call Transcript

PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three month period ended December 31, 2022.

Embecta Corp. Reports First Quarter Fiscal 2023 Financial Results

PARSIPPANY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (NASDAQ: EMBC) have declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 13, 2023 to stockholders of record at the close of business on February 27, 2023.

embecta Announces Quarterly Cash Dividend

Cardinal Health

Chubb

General Electric

GlaxoSmithKline

Illinois Tool Works

Johnson Controls

Kimberly-Clark

Leggett & Platt

Mondelez

Altria

PepsiCo

Philip Morris

Dividends may not increase every year and a cut or elimination is even possible but the odds are greatly reduced when you diversify among different companies and sectors and focus on dividend quality. The market may move up and down irrationally and seemingly on a whim while our dividends remain much more stable, reliable, and predictable.

Dividend Income Update: January 2023

PARSIPPANY, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today announced that management will participate in the following upcoming investor conferences:

embecta to Participate in Upcoming Investor Conferences

NEW YORK , Feb. 6, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Embecta Corp. - EMBC

DexCom

DexCom is young, innovative, admired, and (consequently) highly valued. Embecta is old, lethargic, lacks coverage, and (consequently) lowly valued.

Diabetes Deep-Dive With DexCom And Embecta: Polar Opposite Diabetes Plays

PARSIPPANY, N.J., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spinoff from Becton, Dickinson and Company (“BD”), today held a grand opening ceremony at its new global headquarters office at 300 Kimball Drive, Suite 300, in Parsippany, N.J. The site will be home to members of the leadership team, global support functions and the North America commercial organization. embecta has approximately 2,000 employees worldwide.

embecta opens new global headquarters in Parsippany, N.J.

PARSIPPANY, N.J., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, will host a conference call to discuss its fiscal first quarter 2023 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Tuesday, February 14, 2023.

embecta to Report Fiscal First Quarter 2023 Financial Results

New York, New York--(Newsfile Corp. - January 7, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Embecta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Embecta Corp. - EMBC

Los Angeles, California--(Newsfile Corp. - January 6, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Embecta Corp. ("Embecta" or "the Company") (NASDAQ: EMBC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Embecta Corp. and Encourages Investors with Losses to Contact the Firm

NEW YORK--( BUSINESS WIRE )--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of Embecta stockholders. Our investigation concerns whether Embecta has violated the federal securities laws and/or engaged in other unlawful business practices.

EMBECTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Embecta Corp. on Behalf of Embecta Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--( BUSINESS WIRE )--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of the securities laws.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Embecta Corp. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Embecta Corp. and Encourages Investors with Losses to Contact the Firm

NEW YORK--( BUSINESS WIRE )--The law firm of Kirby McInerney LLP is investigating potential claims against Embecta Corporation (“Embecta” or the “Company”) (NASDAQ: EMBC). The investigation concerns whether Embecta and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Embecta Corp. (EMBC)

Embecta Corp. (NASDAQ:EMBC ) Q4 2022 Earnings Conference Call December 20, 2022 8:00 AM ET Company Participants Pravesh Khandelwal - Vice President of Investor Relations Dev Kurdikar - Chief Executive Officer Jake Elguicze - Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Marie Thibault - BTIG Operator Please standby. Welcome ladies and gentlemen, to the Fiscal Fourth Quarter and Full Year 2022 Embecta Earnings Conference Call.

Embecta Corp. (EMBC) Q4 2022 Earnings Call Transcript

Investors didn't like the diabetes care provider's Q4 update.

Why Embecta Stock Is Sinking Today

PARSIPPANY, N.J., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world, today reported financial results for the three and twelve month periods ended September 30, 2022.

News for Embecta Corp Stock (EMBC)